Sai Yendamuri1,2, Adrienne Groman3, Austin Miller3, Todd Demmy1,2, Mark Hennon1,2, Elisabeth Dexter1,2, Anthony Picone1,2, Chukwumere Nwogu1,2, Grace K Dy4. 1. Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA. 2. Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. 3. Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA. 4. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Abstract
OBJECTIVES: Neoadjuvant therapy has emerged as a favoured treatment paradigm for patients with clinical N2 disease undergoing surgical resection for non-small-cell lung cancer. It is unclear whether such a treatment paradigm affects perioperative outcomes. We sought to examine the National Cancer Database (NCDB) to assess the impact of neoadjuvant therapy on perioperative outcomes and long-term survival in these patients. METHODS: All patients with a history of non-small-cell lung cancer undergoing anatomical resection between 2004 and 2014 were included. Thirty-day and 90-day mortality of all patients having neoadjuvant therapy versus those who did not were compared. In addition, the impact of neoadjuvant therapy on the overall survival of patients with clinical N2 disease was examined. RESULTS: Of the 134 428 selected patients, 9896 (7.4%) patients had neoadjuvant chemotherapy. Patients undergoing neoadjuvant therapy had a higher 30-day (3% vs 2.6%; P < 0.01) and 90-day mortality (6.5% vs 4.9%; P < 0.01). This association remained after adjusting for covariates. Among patients with clinical N2 disease (n = 10 139), 42.3%, 35.3% and 22.4% of patients had neoadjuvant, adjuvant and no chemotherapy, respectively. Univariable, multivariable and propensity score-weighted analyses indicated no difference in survival between patients receiving neoadjuvant and adjuvant chemotherapy. CONCLUSIONS: Neoadjuvant therapy may adversely affect perioperative outcomes without providing a survival advantage compared with adjuvant therapy in clinical N2 stage patients. Randomized controlled trials need to be conducted to examine this issue further.
OBJECTIVES: Neoadjuvant therapy has emerged as a favoured treatment paradigm for patients with clinical N2 disease undergoing surgical resection for non-small-cell lung cancer. It is unclear whether such a treatment paradigm affects perioperative outcomes. We sought to examine the National Cancer Database (NCDB) to assess the impact of neoadjuvant therapy on perioperative outcomes and long-term survival in these patients. METHODS: All patients with a history of non-small-cell lung cancer undergoing anatomical resection between 2004 and 2014 were included. Thirty-day and 90-day mortality of all patients having neoadjuvant therapy versus those who did not were compared. In addition, the impact of neoadjuvant therapy on the overall survival of patients with clinical N2 disease was examined. RESULTS: Of the 134 428 selected patients, 9896 (7.4%) patients had neoadjuvant chemotherapy. Patients undergoing neoadjuvant therapy had a higher 30-day (3% vs 2.6%; P < 0.01) and 90-day mortality (6.5% vs 4.9%; P < 0.01). This association remained after adjusting for covariates. Among patients with clinical N2 disease (n = 10 139), 42.3%, 35.3% and 22.4% of patients had neoadjuvant, adjuvant and no chemotherapy, respectively. Univariable, multivariable and propensity score-weighted analyses indicated no difference in survival between patients receiving neoadjuvant and adjuvant chemotherapy. CONCLUSIONS: Neoadjuvant therapy may adversely affect perioperative outcomes without providing a survival advantage compared with adjuvant therapy in clinical N2 stage patients. Randomized controlled trials need to be conducted to examine this issue further.
Authors: J A Roth; E N Atkinson; F Fossella; R Komaki; M Bernadette Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; W K Hong Journal: Lung Cancer Date: 1998-07 Impact factor: 5.705
Authors: Christopher M Pezzi; Katherine Mallin; Andres Samayoa Mendez; Emmelle Greer Gay; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2014-08-04 Impact factor: 5.209
Authors: Asad A Shah; Mark F Berry; Ching Tzao; Mihir Gandhi; Mathias Worni; Ricardo Pietrobon; Thomas A D'Amico Journal: Ann Thorac Surg Date: 2012-06 Impact factor: 4.330
Authors: Sarah J Gao; Christopher D Corso; Elyn H Wang; Justin D Blasberg; Frank C Detterbeck; Daniel J Boffa; Roy H Decker; Anthony W Kim Journal: J Thorac Oncol Date: 2016-10-05 Impact factor: 15.609
Authors: Chukwumere E Nwogu; Jonathan D'Cunha; Herbert Pang; Lin Gu; Xiaofei Wang; William G Richards; Linda J Veit; Todd L Demmy; David J Sugarbaker; Leslie J Kohman; Scott J Swanson Journal: Ann Thorac Surg Date: 2014-12-10 Impact factor: 4.330
Authors: Daniel C Betticher; Shu-Fang Hsu Schmitz; Martin Tötsch; Eva Hansen; Christine Joss; Christian von Briel; Ralph A Schmid; Miklos Pless; James Habicht; Arnaud D Roth; Anastase Spiliopoulos; Rolf Stahel; Walter Weder; Roger Stupp; Fritz Egli; Markus Furrer; Hanspeter Honegger; Martin Wernli; Thomas Cerny; Hans-Beat Ris Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Athar Battoo; Ariba Jahan; Zhengyu Yang; Chukwumere E Nwogu; Sai S Yendamuri; Elisabeth U Dexter; Mark W Hennon; Anthony L Picone; Todd L Demmy Journal: Chest Date: 2014-11 Impact factor: 9.410
Authors: Ha Eun Kim; Woo Sik Yu; Chang Young Lee; Jin Gu Lee; Dae Joon Kim; Seong Yong Park Journal: Thorac Cancer Date: 2021-12-14 Impact factor: 3.500
Authors: Xin Li; Chunqiu Xia; Minghui Liu; Jinghao Liu; Ming Dong; Honglin Zhao; Song Xu; Dan Wang; Sen Wei; Zuoqing Song; Gang Chen; Hongyu Liu; Jun Chen Journal: Front Oncol Date: 2022-09-13 Impact factor: 5.738